HC Wainwright Has Bearish Forecast for ARWR Q1 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – HC Wainwright dropped their Q1 2026 EPS estimates for Arrowhead Pharmaceuticals in a report released on Tuesday, December 2nd. HC Wainwright analyst P. Trucchio now forecasts that the biotechnology company will earn $1.63 per share for the quarter, down from their prior forecast of $1.83. HC Wainwright currently has a “Buy” rating and a $85.00 target price on the stock. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($2.42) per share. HC Wainwright also issued estimates for Arrowhead Pharmaceuticals’ Q3 2027 earnings at ($1.31) EPS.

A number of other equities analysts have also weighed in on ARWR. Piper Sandler upped their price objective on Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 19th. The Goldman Sachs Group boosted their price target on Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the stock a “neutral” rating in a report on Thursday, November 20th. Bank of America increased their price objective on shares of Arrowhead Pharmaceuticals from $42.00 to $62.00 and gave the company a “buy” rating in a report on Monday. Morgan Stanley boosted their target price on shares of Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 26th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $53.33.

Arrowhead Pharmaceuticals Stock Up 3.0%

ARWR opened at $57.95 on Wednesday. Arrowhead Pharmaceuticals has a fifty-two week low of $9.57 and a fifty-two week high of $59.27. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86. The stock has a market cap of $7.87 billion, a price-to-earnings ratio of -724.28 and a beta of 1.28. The firm’s fifty day moving average is $40.14 and its 200 day moving average is $26.63.

Insiders Place Their Bets

In other news, insider James C. Hamilton sold 20,000 shares of the business’s stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $35.00, for a total value of $700,000.00. Following the sale, the insider directly owned 212,122 shares in the company, valued at $7,424,270. The trade was a 8.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Mauro Ferrari sold 8,750 shares of the company’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $56.39, for a total transaction of $493,412.50. Following the sale, the director owned 68,764 shares in the company, valued at $3,877,601.96. This represents a 11.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 43,750 shares of company stock valued at $1,643,413 over the last three months. Corporate insiders own 4.30% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in Arrowhead Pharmaceuticals by 3.3% during the third quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company’s stock worth $553,077,000 after buying an additional 510,798 shares during the period. Avoro Capital Advisors LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 2.8% in the 3rd quarter. Avoro Capital Advisors LLC now owns 10,900,000 shares of the biotechnology company’s stock worth $375,941,000 after acquiring an additional 300,000 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Arrowhead Pharmaceuticals by 138.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock worth $60,962,000 after purchasing an additional 2,774,933 shares during the period. Geode Capital Management LLC grew its holdings in Arrowhead Pharmaceuticals by 1.0% during the 2nd quarter. Geode Capital Management LLC now owns 2,978,505 shares of the biotechnology company’s stock valued at $47,067,000 after purchasing an additional 28,193 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. raised its position in Arrowhead Pharmaceuticals by 0.9% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 2,528,982 shares of the biotechnology company’s stock worth $32,220,000 after purchasing an additional 21,686 shares during the period. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.